Cryopreserving polymers are provided herein. The cryopreserving polymers comprises polymerized vitamin B5 analogous monomers and a crosslinker such that the crosslinker and the polymerized vitamin B5 analogous monomers are crosslinked. Compositions, cryopreserving colloidal gels, cryopreserving agents comprising the cryopreserving polymers as well as uses thereof are also provided. Methods of cryopreserving cells and methods of preparing the cryopreserving polymer, the compositions, the cryopreserving colloidal gels, and the cryopreserving agents are further provided. The vitamin B5 analogous monomers are defined by formula (I).
Disclosed herein are hydrogels useful for restoring a biological activity of a denatured polypeptide, solubizing one or more protein aggregates, and/or stabilizing a polypeptide, and methods of using the same, wherein the hydrogel comprises a cross-linked polymer prepared by polymerization of a cross-linker and a first monomer of formula I.
A process is described for preparation of tunicate derived CNCs (T-CNCs) which exhibit a high aspect ratio, increased crystallinity and superior thermal properties compared to wood pulp derived CNCs (W-CNCs). The process enables scalable isolation of T-CNCs from tunicates, and a solution to the challenge invasive tunicates pose to aquaculture communities.
A process is described for preparation of tunicate derived CNCs (T-CNCs) which exhibit a high aspect ratio, increased crystallinity and superior thermal properties compared to wood pulp derived CNCs (W-CNCs). The process enables scalable isolation of T-CNCs from tunicates, and a solution to the challenge invasive tunicates pose to aquaculture communities.
Hygroscopic hydrogels including a cross-linked polymer, the polymer being prepared by polymerization of one or more monomers, wherein at least one of the monomers is a compound of formula I, are provided. Related monomers and polymers, as well as methods for the production and use thereof, are also provided. Hygroscopic hydrogels as described herein may be used for water harvesting, for example. (I) (formula I)
Hygroscopic hydrogels including a cross-linked polymer, the polymer being prepared by polymerization of one or more monomers, wherein at least one of the monomers is a compound of formula I, are provided. Related monomers and polymers, as well as methods for the production and use thereof, are also provided. Hygroscopic hydrogels as described herein may be used for water harvesting, for example. (I) (formula I)
C07C 235/10 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
Disclosed herein are hydrogels useful for restoring a biological activity of a denatured polypeptide, solubizing one or more protein aggregates, and/or stabilizing a polypeptide, and methods of using the same, wherein the hydrogel comprises a cross-linked polymer prepared by polymerization of a cross-linker and a first monomer of formula I.
Disclosed herein are hydrogels useful for restoring a biological activity of a denatured polypeptide, solubizing one or more protein aggregates, and/or stabilizing a polypeptide, and methods of using the same, wherein the hydrogel comprises a cross-linked polymer prepared by polymerization of a cross-linker and a first monomer of formula I.
The present disclosure provides a dual-drag-containing nanoparticle, in which a first antiviral drag, such as remdesivir and a second antiviral drag are co-encapsulated and co-delivered by the nanoparticle, said nanoparticle comprising an alginate-oleic acid particle. The disclosure also relates to the therapeutic use of the nanoparticle in treating viral infections, such as SARS-CoV-2.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A print head for a 3D printer can receive a syringe of printing material which controllably exits through a needle or nozzle. The print head has a misting port through which a mist of the chemical cross-linker flows around the printing material for curing. The print head further includes an extraction port for extracting excess chemical cross from around the printed object.
B29C 64/00 - Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
Hygroscopic hydrogels including a cross-linked polymer, the polymer being prepared by polymerization of one or more monomers, wherein at least one of the monomers is a compound of formula I, are provided. Related monomers and polymers, as well as methods for the production and use thereof, are also provided. Hygroscopic hydrogels as described herein may be used for water harvesting, for example. (I) (formula I)
C07C 69/533 - Monocarboxylic acid esters having only one carbon-to-carbon double bond
C07C 235/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07C 321/18 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
C07D 233/10 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
C08F 20/60 - Amides containing nitrogen in addition to the carbonamido nitrogen
Hygroscopic hydrogels including a cross-linked polymer, the polymer being prepared by polymerization of one or more monomers, wherein at least one of the monomers is a compound of formula I, are provided. Related monomers and polymers, as well as methods for the production and use thereof, are also provided. Hygroscopic hydrogels as described herein may be used for water harvesting, for example. (I) (formula I)
C07C 235/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
C02F 1/28 - Treatment of water, waste water, or sewage by sorption
C07C 321/18 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
C07C 69/533 - Monocarboxylic acid esters having only one carbon-to-carbon double bond
C07D 233/10 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
C08F 20/60 - Amides containing nitrogen in addition to the carbonamido nitrogen
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
A print head for a 3D printer can receive a syringe of printing material which controllably exits through a needle or nozzle. The print head has a misting port through which a mist of the chemical cross-linker flows around the printing material for curing. The print head further includes an extraction port for extracting excess chemical cross from around the printed object.
A print head for a 3D printer can receive a syringe of printing material which controllably exits through a needle or nozzle. The print head has a misting port through which a mist of the chemical cross-linker flows around the printing material for curing. The print head further includes an extraction port for extracting excess chemical cross from around the printed object.
Provided is a device for flipping or rotating a floating aquatic cage to mitigate biofouling, and for farm management, such as to carry out maintenance and facilitate harvesting, particularly the style of floating cage used in farming oysters and other shellfish. The device includes a hollow frame or housing which defines a path through which the floating aquatic cage may pass, including entrance and exit openings; and one or more guide elements positioned on an inside surface of the hollow frame or housing. The one or more guide elements form an obstruction to opposing corners of the floating aquatic cage, and impart a turning force in such a manner as to rotate the floating aquatic cage.
A hand-portable test apparatus includes an in-the-field test processing assembly, and a lab-on-a-chip test cartridge having a neutralising zone, a specific reagent mixing zone, and a testing chamber. It has a convective heating loop for thermal cycling. There are two passive self-actuating valves that allow the test chamber volume to fill with solution, but then close to meter and trap the solution. The apparatus has external illumination ports, and an optical sensing port. Each cartridge is uniquely identified. It has smooth surfaces that allow adhesive membranes to be used to permit the pre-loading of reagents, prevent evaporation, and permit preservation of results. The test apparatus includes a holder for the cartridge with a heater, illumination, and optical sensor units closely positioned relative to the holder. There is a wiring circuit board, a processor, and a power supply. All of the items are contained within a unitary housing.
A hand-portable test apparatus includes an in-the-field test processing assembly, and a lab-on-a-chip test cartridge having a neutralising zone, a specific reagent mixing zone, and a testing chamber. It has a convective heating loop for thermal cycling. There are two passive self-actuating valves that allow the test chamber volume to fill with solution, but then close to meter and trap the solution. The apparatus has external illumination ports, and an optical sensing port. Each cartridge is uniquely identified. It has smooth surfaces that allow adhesive membranes to be used to permit the pre-loading of reagents, prevent evaporation, and permit preservation of results. The test apparatus includes a holder for the cartridge with a heater, illumination, and optical sensor units closely positioned relative to the holder. There is a wiring circuit board, a processor, and a power supply. All of the items are contained within a unitary housing.
A hand-portable test apparatus includes an in-the-field test processing assembly, and a lab-on-a-chiptest cartridge having a neutralising zone, a specific reagent mixing zone, and a testing chamber. It has a convective heating loop for thermal cycling. There are two passive self-actuating valves that allow the test chamber volume to fill with solution, but then close to meter and trap the solution. The apparatus has external illumination ports, and an optical sensing port. Each cartridge is uniquely identified. It has smooth surfaces that allow adhesive membranes to be used to permit the pre-loading of reagents, prevent evaporation, and permit preservation of results. The test apparatus includes a holder for the cartridge with a heater, illumination, and optical sensor units closely positioned relative to the holder. There is a wiring circuit board, a processor, and a power supply. All of the items are contained within a unitary housing.
Described herein is a device for flipping or rotating a floating aquatic cage to mitigate biofouling, and for farm management, such as to carry out maintenance and facilitate harvesting, particularly the style of floating cage used in farming oysters and other shellfish. The device comprises a hollow frame or housing which defines a path through which the floating aquatic cage may pass, including entrance and exit openings; and one or more guide elements positioned on an inside surface of the hollow frame or housing. The one or more guide elements form an obstruction to opposing corners of the floating aquatic cage, and impart a turning force in such a manner as to rotate the floating aquatic cage.
Described herein is a device for flipping or rotating a floating aquatic cage to mitigate biofouling, and for farm management, such as to carry out maintenance and facilitate harvesting, particularly the style of floating cage used in farming oysters and other shellfish. The device comprises a hollow frame or housing which defines a path through which the floating aquatic cage may pass, including entrance and exit openings; and one or more guide elements positioned on an inside surface of the hollow frame or housing. The one or more guide elements form an obstruction to opposing corners of the floating aquatic cage, and impart a turning force in such a manner as to rotate the floating aquatic cage.
There is provided herein compounds of formula I, wherein R1 is H or linear or branched C1-C6 lower alkyl; R2 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R3 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R4 is -OH or -O-R5 wherein R5 is linear or branched C1-C6 lower alkyl; and each R6 is independently H or -CH3; or a pharmaceutically acceptable prodrug, salt, or ester thereof. Compositions containing said compounds, and uses thereof, are also provided. (I)
There is provided herein compounds of formula I, wherein R1 is H or linear or branched C1-C6 lower alkyl; R2 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R3 is H, linear or branched C1-C6 lower alkyl, or a proteinogenic amino acid side chain; R4 is -OH or -O-R5 wherein R5 is linear or branched C1-C6 lower alkyl; and each R6 is independently H or -CH3; or a pharmaceutically acceptable prodrug, salt, or ester thereof. Compositions containing said compounds, and uses thereof, are also provided. (I)
Described are covalent conjugates between lipoic acid (LA), or a derivative thereof, and resveratrol, or a derivative thereof. As an example, the covalent conjugate may be a compound of the formula: (I). Methods using the LA-resveratrol conjugates for the treatment of diseases, disorders, or conditions related to oxidative stress are also provided.
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07C 323/00 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
C07C 327/28 - Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
Covalent conjugates between lipoic acid (LA), or a derivative thereof, and edaravone, or a derivative thereof, are disclosed, including compounds of Formula I: (I) Therapeutic methods using the LA-edaravone conjugates are also described, including for the treatment of diseases, disorders, or conditions related to oxidative stress.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
27.
MULTIPLEX DIAGNOSTIC ASSAY FOR DETECTING SALMONID PATHOGENS
A method is provided for detecting the presence or absence of salmonid pathogens, including Infectious Hematopoietic Necrosis Virus (IHNV), Infectious Pancreatic Virus (IPNV), Infectious Salmon Anemia Virus (ISAV), Salmon Alphaviruses (SAV), Viral Hemorrhagic Septicemia Virus (VHSV), and Renibacterium salmoninarum. The method includes steps which may be carried out using a variety of analytical techniques, such as multiplexing RT-PCR, Target Specific Primer Extension (TSPE), and fluidic bead-based technology. PCR primers and TSPE primers which are components of the multiplex diagnostic assay using fluidic bead-based technology for detection of salmonid pathogens are also described.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
Described herein is an apparatus and method for ischemic muscle training or recovery by coordinated blood flow restriction and electrical muscle stimulation. The apparatus comprises a blood flow occluding element for restricting blood flow to a target muscle or muscle group in a user, and measuring resting systolic blood pressure (SBP); and an electrical muscle stimulator comprising at least one electrode and a control unit which, upon activation, is effective to send low amplitude electric pulses through the target muscle or muscle group forcing the targeted muscle to contract while the blood flow is restricted.
Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and related medical uses are also described.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A method is described for measuring symptoms in a rodent model of Autism Spectrum Disorders and comorbid conditions. The method comprises measuring deficits in one or more developmental, communication, social behaviour and abnormally repetitive behaviour phenotype, together with at least one measurement of Ultrasonic Vocalizations (USVs).
The present application relates to novel apocynin-lipoic acid covalent conjugates, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions that are mediated by oxidative stress. In particular, the present application includes compounds of Formula (I), and compositions and uses thereof.
C07D 339/04 - Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61P 39/06 - Free radical scavengers or antioxidants
C07C 323/52 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
32.
IRON BISPHENOLATE COMPLEXES AND METHODS OF USE AND SYNTHESIS THEREOF
The present application, relates to iron bisphenolate complexes and methods of use and synthesis thereof. The iron complexes are prepared from tridentate or tetradentate ligands of Formula I: wherein R1 and R2 are as defined herein. Also provided are methods and processes of using the iron bisphenolate complexes as catalysts in cross-coupling reactions and in controlled radical polymerizations.
C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 217/08 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
C08F 4/80 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from metals not provided for in group selected from iron group metals or platinum group metals
An animal stroke model is provided. The model is useful in the study of brain ischemia and/or reperfusion injury and in identification and testing of compounds and interventions useful in the treatment of stroke. The method is carried out in a non-human mammal, such as rat. The method of inducing ischemia and/or reperfusion injury involves exposing a portion of the middle cerebral artery (MCA) and temporarily occluding it at one or more distinct locations, preferably three distinct locations. The model results in highly reproducible and focal infarct sizes, with low rate of mortality during the experimental procedure.
A01K 67/027 - New or modified breeds of vertebrates
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
34.
PREPARATION AND USE OF PSEUDOPTEROXAZOLE AND PSEUDOPTEROSIN ANALOGS AND DERIVATIVES
New methods of converting pseudopterosins to pseudopteroxazoles have been developed and used to make several new non-natural pseudopteroxazole analogs. These as well as pseudopterosins and derivatives thereof and prenylated aromatic structural mimics of pseudopterosins/pseudopteroxazoles are shown to display anti-bacterial activity including that against non-replicating mycobacteria, with some exhibiting no or limited toxicity against mammalian cells.
C07D 263/52 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
C07C 215/88 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems being formed by at least three rings
C07C 49/747 - Unsaturated compounds containing a keto group being part of a ring containing hydroxy groups containing six-membered aromatic rings
C07D 235/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
C07D 241/38 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
An animal stroke model is provided. The model is useful in the study of brain ischemia and/or reperfusion injury and in identification and testing of compounds and interventions useful in the treatment of stroke. The method is carried out in a non-human mammal, such as rat. The method of inducing ischemia and/or reperfusion injury involves exposing a portion of the middle cerebral artery (MCA) and temporarily occluding it at one or more distinct locations, preferably three distinct locations. The model results in highly reproducible and focal infarct sizes, with low rate of mortality during the experimental procedure.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
A01K 67/027 - New or modified breeds of vertebrates
36.
PROCESS FOR CONTROLLED RADICAL POLYMERIZATION USING A VANADIUM CATALYST
The controlled radical polymerization of functionalized vinyl monomers is described. The polymerization takes place in the presence of a free radical initiator and a vanadium based catalyst. Suitable monomers include styrenes, acrylates, methacrylates, acrylonitrile and isobutylene. The vanadium based catalyst comprises a non-innocent ligand. In preferred embodiments, the non-innocent ligand is selected from the group consisting of alpha-diimine ligands, 1,2-dithiolate ligands, 2,2'-bipyridine ligands, porphyrins, pthalocyanines, dioxalenes, dithiolenes and bis(imino)pyridines.
C08F 4/76 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from metals not provided for in group selected from refractory metals selected from titanium, zirconium, hafnium, vanadium, niobium, or tantalum
Disclosed is a method for synthesizing star polymers having controlled tacticity. The method comprises reacting a lactone-based monomer having at least one stereocentre and a poly -functional initiator in the presence of at least one catalyst. In particular embodiments, the lactone-based monomer is L-lactide or DL-lactide, the poly -functional initiator is dipentaerythritol, and the at least one catalyst is an aluminum-salen catalyst (tBu[O,N,N,O] A1Me) or an aluminum-salan catalyst (Cl[O,N,N,O] A1Me). Star polymers comprising at least two arms and having heterotacticity bias, isotacticity bias, or stereoblocks of different tacticity bias are produced. Such star polymers are useful, for example, in controlled delivery of bioactive molecules
A method of modeling in vitro focal ischemia comprising: perfusing a tissue slice in vitro with an oxygenated medium; and, applying a focal insult to a targeted portion of the tissue slice. The method is particularly useful for brain tissue.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
41.
Identification of immunoglobulin (lg) disorders using fourier transform infrared spectroscopy
A method and a corresponding system for obtaining a serum mid-infrared spectroscopic profile using Fourier-transform infrared spectroscopy (FTIR) are described. The method comprises acquiring FTIR spectra for dried sera and preprocessing the FTIR spectra of sera by differentiation and smoothing to enhance weak spectral features and to remove baseline variations. The preprocessed FTIR spectra are normalized to a common intensity range, the normalization being performed in a spectral sub-region defined by strongest infrared (IR) absorption for a protein to obtain the serum spectroscopic profile. The serum spectroscopic profiles provide a basis to diagnose immunoglobulin disorders or to quantify serum immunoglobulin levels.
A method and a corresponding system for obtaining a serum mid-infrared spectroscopic profile using Fourier-transform infrared spectroscopy (FTIR) are described. The method comprises acquiring FTIR spectra for dried sera and preprocessing the FTIR spectra of sera by differentiation and smoothing to enhance weak spectral features and to remove baseline variations. The preprocessed FTIR spectra are normalized to a common intensity range, the normalization being performed in a spectral sub- region defined by strongest infrared (IR) absorption for a protein to obtain the serum spectroscopic profile. The serum spectroscopic profiles provide a basis to diagnose immunoglobulin disorders or to quantify serum immunoglobulin levels.
G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solidsPreparation of samples therefor
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
Clonal strains of bacteria derived from Pseudopterogorgia elisabethae are capable of making pseudopterosins in in vitro cultures without requiring the presence of other bacteria, algae, or animal cells that are normally present in P. elisabethae.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
C07H 15/24 - Condensed ring systems having three or more rings
C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
